



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 9/20</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 92/19227</b> <b>(43) International Publication Date:</b> 12 November 1992 (12.11.92)
<b>(21) International Application Number:</b> PCT/EP92/01024 <b>(22) International Filing Date:</b> 2 May 1992 (02.05.92)  <b>(30) Priority data:</b> 9109862.4 8 May 1991 (08.05.91) GB  <b>(71) Applicant (for MG only):</b> SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).  <b>(71) Applicant (for all designated States except US):</b> LABORATORIOS BEECHAM SA [ES/ES]; Costa Brava, 14, 28034 Madrid (ES).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> MARTIN, Luis, Carvajal [ES/ES]; Ronda de Buenavista, 26, E-45007 Toledo (ES). ROMERO, Juan, Dedios [ES/ES]; SB Pharmaceuticals, Poligono Industrial, E-45007 Toledo (ES).		<b>(74) Agent:</b> WALKER, Ralph, Francis; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).  <b>(81) Designated States:</b> AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC (European patent), MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, RU, SD, SE, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> PHARMACEUTICAL FORMULATIONS  <b>(57) Abstract</b>  Tablet formulations having a structure comprising compacted granulates of a mixture of a medicament and an intra-granular disintegrant, the granulates being compacted together into a tablet with an extra-granular disintegrant and optional extra-granular lubricant and excipients.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

PHARMACEUTICAL FORMULATIONS

The present invention relates to pharmaceutical formulations for oral administration in the treatment of bacterial infections, and to processes for the manufacture of such formulations.

It is known to provide formulations for oral administration in the form of water-dispersible granules or tablets which may be swallowed or dispersed in water prior to swallowing.

In one known method of tablet manufacture, an intermediate granulate is prepared comprising an intragranular disintegrant and an active material such as an antibiotic. This granulate is then mixed with an intergranular disintegrant (and optional other additives including a lubricant) and compressed into tablets. Such a process, tablets and granulate are for example described in EP 0281200A, CA 1199871 and JP 3240023A.

It is desirable that such solid formulations should rapidly disperse on immersion in water, for example by rapid disintegration of tablets.

Novel formulations have now been discovered which assist in achieving some of the above-mentioned desirable features.

The invention therefore provides a tablet formulation having a structure comprising compacted granulates; the granulates comprising at least one compacted medicament optionally together with an intra-granular disintegrant; the granulates being compacted together into a tablet form together with an extra-granular disintegrant and optionally also together with an extra-granular lubricant, provided that if a lubricant is present the amount of lubricant is less than 0.5% by weight of the total tablet.

In the tablets of this invention the granulates may be in a crushed state resulting from the compaction of the tablet, and consequently may not have discrete boundaries, or may be sub-divided or broken up into smaller granulates. The invention is intended to include tablets having such a structure containing crushed granulates. Preferably the size of the granulates is in the range 100 $\mu$ m to 2mm, suitably around 1mm  $\pm$  0.25mm, maximum dimension.

The medicament is preferably one which is capable of oral absorption, in particular  $\beta$ -lactam antibiotics optionally in combination with a  $\beta$ -lactamase inhibitor. A preferred antibiotic is amoxycillin, for example present as a hydrate such as the trihydrate. Amoxycillin may be used alone, or may optionally be used in combination with other  $\beta$ -lactam antibiotics and/or  $\beta$ -lactamase inhibitors such as clavulanic acid or salts (especially the potassium salt) thereof, for example in a weight ratio equivalent to amoxycillin: clavulanic acid in the range 12:1 to 1:1 such as around 4:1 or 2:1. Preferably the proportion of the antibiotic in the tablet is 60-98% by weight of the total tablet, in the case of amoxycillin trihydrate calculated as the weight of the trihydrate. Preferably the particles of antibiotic in the granulates are in the size range  $1\mu\text{m}$  to  $300\mu\text{m}$ , especially  $10\mu\text{m}$  to  $200\mu\text{m}$ . A typical suitable size distribution of the antibiotic particles is :  $>200\mu$  5% or less,  $200-100\mu$  5-15%,  $100-50\mu$  7.5-15%,  $<50\mu$  70% or more.

Suitable intra-granular disintegrants are starches, such as maize starch and rice starch, cross-linked N-vinyl-2-pyrrolidone ("CLPVP"), sodium starch glycollate, croscarmellose sodium and formaldehyde - casein, or combinations thereof. A preferred intra-granular disintegrant is CLPVP, for example as marketed under the trade names Polyplasdone XL and Polyplasdone XL-10.

The granulate may consist entirely of antibiotic(s), optionally in the case of a  $\beta$ -lactam antibiotic combined with a  $\beta$ -lactamase inhibitor, and an intra-granular disintegrant. Alternatively, particularly when the granulate contains clavulanic acid or a salt thereof, the granulate may also contain a diluent such as silica gel (eg Syloid-Trade Mark). Suitable intra-granular disintegrants for use with antibiotics are CLPVP and sodium starch glycollate. Typically the proportion of intra-granular disintegrant in the granulate may be 0.1 - 10wt % of the granulate, suitably 1.0 - 8.0wt %, such as 1.25 - 3.5wt %. Typically the proportion of an antibiotic or antibiotic +  $\beta$ -lactamase inhibitor combination in the granulate may be 99.9 - 90wt %, suitably 99 - 92wt %, e.g. 99 - 95wt %, such as 98.75 - 96.5wt % of the weight of the granulate. When the granulate contains a diluent, this may comprise up to 30wt % of the granulate, but is conveniently present in a 1:1 weight ratio with the

- 3 -

amount of clavulanic acid or its salt in the granulate. When the granulate contains a diluent the granulate will contain a correspondingly lower proportion of antibiotic or antibiotic +  $\beta$ -lactamase inhibitor combination, for example 70 - 99.9wt % of the granulate.

5

The intimate contact between the antibiotic and the intra-granular disintegrant in the granulate appears to assist in improved disintegration and dispersion of the granulate in contact with water to release antibiotic particles in the size range referred to above, and to provide finely dispersed suspensions. Problems are associated with preparation of granulates which include clavulanic acid or its salts, due to their hygroscopicity, and the granulate of the invention facilitates manufacture.

10  
15

In the tablet formulation the granulate may suitably comprise 70% or more, e.g. 80% or more, 90% or more or 95% or more of the total tablet weight so that a high proportion of medicament is present.

20

25

30

The extra-granular disintegrant may be a conventional disintegrant for example starches such as maize-starch and rice starch, CLPVP, sodium starch glycollate, croscarmellose sodium, microcrystalline or microfine cellulose, low-substituted hydroxypropylcellulose (i.e. cellulose partially substituted with 2-hydroxypropyl groups, e.g. less than 25% substituted, preferably 7-16% substituted), cross-linked sodium carboxymethylcellulose, swellable ion exchange resins, formaldehyde-casein, or alginates. Preferred extra-granular disintegrants are CLPVP, sodium starch glycollate, microfine cellulose and croscarmellose sodium, and combinations thereof. An example of an extra-granular disintegrant combination is a combination of microcrystalline or microfine cellulose with sodium starch glycollate, croscarmellose sodium, or CLPVP, containing 80-90% by weight cellulose.

35

The proportion of extra-granular disintegrant to total tablet weight may vary between broad limits, for example 0.1-25 weight %. For example if CLPVP or sodium starch glycollate is used as extra-granular disintegrant it may suitably be used as such in a proportion 0.1-5.0 weight %, suitably 0.1 - 3.0 weight %, preferably 0.1-1.5 weight % of the total tablet weight. If cellulose or a combination containing cellulose is used, e.g. as described above containing around 80-90% by weight of cellulose, the extra-granular

disintegrant may comprise 1-25 weight %, typically around 1-20 weight % of the total tablet.

5 Suitable lubricants are those conventional to the art, such as long-chain fatty acids, such as stearic acid, or salts thereof, in particular Group II metal salts, such as of magnesium or calcium.

10 A preferred lubricant is magnesium stearate. It is preferred to use a lubricant proportion as low as possible e.g. 0.35% by weight or preferably lower, e.g. 0.275% or less, e.g. 0.25% or less, preferably using no lubricant at all.

15 The granulate may also contain an intra-granular lubricant, which may be selected from the same materials as the extra-granular lubricant, such as magnesium stearate. However an advantage of the present tablet formulation is that the granulate and tablet need not contain any lubricant. This can lead to improved wettability and hence improved disintegration of the tablet. Further a reduced lubricant proportion can lead to a lower tablet weight for a given dose of antibiotic and in the case of dispersible formulations can avoid the "smeared" appearance associated with higher lubricant proportions.

25 The tablet may also include conventional excipients, typically present up to about 10% of the total tablet weight. These may include flavouring agents, for example flavourings such as menthol, peppermint, vanilla or fruit flavourings, flavouring agents typically being present up to around 0.5-5% by weight of the whole tablet, and sweeteners, e.g. aspartame, present of up to around 15mg per unit dose. Excipients may also include colouring agents, preservatives, suspending aids and fillers such as silicon dioxide, microcrystalline cellulose, dicalcium phosphate, lactose, sorbitol, calcium carbonate or magnesium carbonate. Such excipients are preferably mixed with the extra-granular disintegrant and lubricant (if present). The materials present in the tablets should have low free moisture content and preferably be pre-dried. In some cases, particularly when the medicament is an antibiotic, and includes clavulanic acid or its salts, it may be necessary to include a dessiccant diluent such as silica gel as an excipient, in a proportion of about 1-5% of the weight of the antibiotic, mixed with the antibiotic and intra-granular disintegrant in

the granulates. The particle size of the excipients does not appear to be critical but it is desirable to exclude agglomerates.

5 The tablet may also contain an effervescent couple of known type, e.g. a solid acid and an alkali metal carbonate or bicarbonate which generates carbon dioxide on contact with water to assist in disintegration of the tablet.

10 The tablets may be film coated in a conventional manner, e.g. for cosmetic, palatability or production purposes. Suitable coatings include hydroxypropylcellulose, acrylate and/or methacrylate co-polymers, resins etc. Alternatively the coating may be an enteric coating, e.g. which is insoluble in acidic gastric juice but soluble in alkaline digestive juice. Such a coating enables the antibiotic to pass through the stomach into the  
15 duodenum, from where it is absorbed. Suitable enteric coatings include cellulose acetate phthalate.

Preferred combinations of components for the tablets of this aspect of the invention therefore comprise:

20

<u>Granulate:</u> <u>Component</u>	<u>wt%</u>	<u>Example</u>
Medicament	70 - 99	Amoxycillin ± Pot.clavulanate
Disintegrant	0.1 - 4	CLPVP, Microcryst. cellulose, sodium starch glycollate
Diluent	0 - 30	Silica gel

<u>Tablet:</u> <u>Component</u>	<u>wt%</u>	<u>Example</u>
Granulate	70+	above
Disintegrant	0.1 - 25	CLPVP, Microcryst. cellulose, sodium starch glycollate.
Lubricant	0 - 0.35	Magnesium stearate
Excipients	to 100	Aspartame, flavour, colour, silicon dioxide

5 The invention also provides a process for the manufacture of a tablet in  
 which granulates comprising a compacted mixture of at least one  
 medicament such as a  $\beta$ -lactam antibiotic either alone or in combination  
 with a  $\beta$ -lactamase inhibitor, together with an intra-granular disintegrant  
 are mixed with an extra-granular disintegrant and optionally with an  
 extra-granular lubricant and optionally with any excipients, provided that  
 10 if a lubricant is present it amounts to less than 0.5% by weight of the  
 mixture, and the mixture is compressed into tablets.

Suitable and preferred antibiotics, intra- and extra-granular  
 disintegrants, lubricants, excipients, granulate and particle sizes, and  
 relative proportions thereof are as discussed above.

15

The necessary granulate for the process of this aspect of the invention



may be made in a further process by mixing the medicament in a powdered form with the intra-granular disintegrant in a dry state, and compacting the mixture under pressure. Insofar as this further process uses as intra-granular disintegrant CLPVP, sodium starch glycollate, casein-formaldehyde, croscarmellose sodium or combinations thereof, it is  
5 believed to be novel, and is a further aspect of this invention.

In this further process, it is desirable to mill and sieve the antibiotic to achieve the desired particle size range. It is also desirable to mill and sieve intra-granular disintegrant to a suitable particle size, for example in  
10 the case of CLPVP about 30 $\mu$ , but particle size does not appear to be critical.

The compaction of the mixture into granulates may be by conventional dry compaction means, for example pressing, rolling, slugging extrusion etc, and a suitable pressure for the compaction process is 30-200KN, e.g. 35-65KN preferably 40-50 KN. The above-described granulate formulations are particularly suited to formation by roller compaction. It may be necessary to mill and sieve the compacted mixture after  
20 compaction so as to achieve a suitable size fraction of the granulate. Compression into tablets may be carried out in a conventional manner, e.g. on a conventional tableting machine. As an optional further step the tablets may be coated as described above.

25 When the granulates described above contain as a medicament a  $\beta$ -lactam antibiotic such as amoxycillin together in combination with a  $\beta$ -lactamase inhibitor such as clavulanic acid or its salts (especially potassium clavulanate) these granulates are believed to be novel and are a further aspect of this invention. Suitable and preferred features of these granules  
30 are as discussed above.

The granulates described above may be suitable for use in the preparation of other pharmaceutical formulations in addition to tablets, for example they may be supplied as a free-flowing granulated formulation in sachets  
35 containing a suitable unit dose. This may also for example be dissolved in water together with excipients such as sweetening agents, thickeners, preservatives and buffers such as sodium benzoate, sodium acetate and sodium citrate to form a syrup formulation, for example for administration

to small children.

5 The ability of the granulates to form a loose compact, and their rapid dispersion in contact with water makes them particularly suitable for use in encapsulated formulations. Therefore in a further aspect of this invention there is provided an encapsulated formulation comprising such granulates. The encapsulated formulation may optionally include an extra-granular lubricant, which if present is suitably in an amount of less than 0.5% by weight of the granulates, being contained within a  
10 pharmaceutical capsule.

The medicament is preferably one which is capable of oral absorption, in particular a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor. Suitable and preferred antibiotics,  $\beta$ -lactamase  
15 inhibitors, intra-granular disintegrant, extra-granular lubricant, granulate and particle sizes, and relative proportions thereof for a capsule formulation are as discussed above, except that a preferred proportion of lubricant is 0.1-0.5%, particularly 0.32-0.35% by weight of the granulate.

20 The pharmaceutical capsule may be an entirely conventional capsule, capable of dissolving in the stomach to release its contents, for example made of gelatine.

The formulations described above preferably contain unit doses of  
25 antibiotic, for example 375, 500, 750 or 1000mg of amoxycillin per tablet or capsule. The tablets may be dispersed in water prior to ingestion, or may alternatively be chewed or swallowed whole.

30 The invention further provides a pharmaceutical formulation as described above, for use as an active therapeutic substance.

The invention further provides a pharmaceutical formulation as described above, in which the medicament is a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, for use in the treatment of  
35 bacterial infections.

The invention further provides a method of use of a pharmaceutical formulation as described above in which the medicament is a  $\beta$ -lactam

antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor in the manufacture of a medicament for use in the treatment of bacterial infections.

- 5 The invention further provides a method of treatment of bacterial infections in mammals which comprises the administration to the mammal of an effective amount of a pharmaceutical formulation as described above, in which the medicament is a  $\beta$ -lactam antibiotic, optionally in combination with a  $\beta$ -lactamase inhibitor.

10

The invention will now be described by way of example only.

Example 1: Granulate.

- 15 Amoxycillin trihydrate was milled and sieved using an 0.04 or 0.027 inch (1.0 - 0.7 mm) aperture sieve, and was mixed for 15 minutes in a blender with dried cross-linked polyvinylpyrrolidone having a molecular weight of approximately 1 million and a density of 1.22 mg/cm<sup>3</sup> (polyplasdone XL - Trade Mark), the mixture containing 3.4% of CLPVP by weight.

20

The mixture was consolidated using a roller compacter at a controlled pressure of 50KN. The compacted flakes were granulated in a mill, or granulated through a sieve fitted with a 1mm mesh to obtain a suitable size fraction.

25

Example 2: Tablet.

Tablets were prepared having the composition below;

<u>Component</u>	<u>Weight mg.</u>	<u>Weight %</u>
Amoxycillin trihydrate	750 <sup>1</sup>	78.95
CLPVP	26.0	2.73
Sodium Starch	21.6	2.27
Glycollate (Primogel)		
Magnesium Stearate	2.0	0.21
Aspartame	20.0	2.10

as granulate of  
example 1

extra granulate

Microcrystalline	130.4	13.74
Cellulose (Avicel PH102)		

(1) Expressed or free acid equivalent:

- 5 To prepare these tablets, the dried sodium starch glycollate, magnesium stearate and microcrystalline cellulose were sieved, then blended with the granulate of example 1. The aspartame was then added, and this mixture was then blended until homogeneous (5 minutes). The mixture was then compressed into tablets on a conventional tableting machine.

Example 3: Granulate.

10

A granulate was prepared using a procedure identical to example 1, comprising 97 weight % of amoxycillin trihydrate and 3 weight % polyplasdone XL, and using a controlled pressure of 40-50 KN.

15 Example 4: Tablet.

Tablets were prepared having the composition below:

Component	wt. mg	wt. mg	wt. mg	wt. mg	wt. %
Amoxycillin	375	500	750	1000	83.00 <sup>1</sup>
CLPVP	17.5	23.33	35	46.65	3.78 <sup>2</sup>
Peppermint dry flavour	3	4	6	7.99	0.65
Aspartame	7.5	10	15	19.99	1.62
Magnesium stearate	1	1.34	2	2.67	0.21

- 20 (1) As 95 wt. % of amoxycillin trihydrate.  
(2) 3% as intra-granular, and 0.78% as extra-granular disintegrant.

- 25 To prepare these tablets, the dried flavour, aspartame, magnesium stearate and a weight of CLPVP (polyplasdone XL) corresponding to 0.78 wt. % of the total weight of the mixture was mixed for 5 minutes with the granulate of example 3 to give the wt % indicated above. The mixture was then compressed into tablets on a conventional tableting machine.

Typical tablets of this example containing 750mg of amoxycillin as the trihydrate had the following characteristics:

weight	:	925mg $\pm$ 5%
hardness	:	> 16 KP
time of dispersal :		< 1 minute
in water		
friability	:	<1%
presentation	:	Oval, 17 x 10 x 7mm tablets

5

#### Example 5: Granulate

A granulate was prepared using a procedure identical to that of example 1, comprising 97.12 weight % amoxycillin trihydrate together with 2.88 weight % sodium starch glycollate (as "Primogel") as intra-granular disintegrant.

10

#### Example 6: Tablet

15 Tablets were prepared having the composition below:

<u>Component%</u>	<u>Weight mg.</u>	<u>Weight %</u>
Amoxycillin	750mg <sup>1</sup>	78.95
Sodium starch glycollate	21.6mg	2.27
		as granulate of example 5
Magnesium stearate	2.0mg	0.21
Dried microcrystalline cellulose (Avicel PH102)	to 950mg	18.57
		extra granulate

(1) As free acid equivalent

20 To prepare these tablets, the granulate of example 5 was sieved using a 1mm sieve, and was then blended with appropriate quantities of the magnesium stearate (lubricant) and microcrystalline cellulose, mixing for 15 minutes. The mixture was then compacted to form tablets having the

following characteristics:

weight	:	950mg
hardness	:	12 - 16 KP
time of dispersal	:	10-15 seconds (37°C),
in water	:	20-25 seconds (20°C)

- 5 These tablets could be provided in the above-described uncoated state for dispersion in water prior to swallowing, or could be film coated for swallowing.

#### Example 7: Encapsulated Formulation

- 10 The granulate of example 3 was made up into a loose compact under gentle pressure together with an amount of magnesium stearate lubricant to total 0.34% by weight of the total compact. This loose compact was sealed into gelatin capsules containing the following mixture:

<u>Component</u>	<u>Weight mg.</u>	<u>Weight %</u>
Amoxycillin trihydrate:	573.91 <sup>1</sup>	96.8
CLPVP :	17	2.9
magnesium stearate :	2	0.34

(1) corresponds to 500mg  
amoxycillin free acid

15

#### Example 8: Sachet Formulation

<u>Component</u>	<u>Weight mg.</u>	<u>Weight %</u>
Amoxycillin trihydrate		76.12 granulate
Potassium	2711.1	
clavulanate/syloid AL-1		
blend 1:1		
Polyplasdone XL dried		0.38
Polyplasdone XL dried	13.5	
Lemon dry flavour	408.0	
		11.45 extra granular

- 13 -

Strawberry dry flavour	132.0	3.71
Peach dry flavour	102.0	2.86
Aspartame	45.0	1.26
Xantham Gum	150.0	4.21

Granules were in a manner identical to that of example 1, i.e. by milling and sieving of the granulate components, followed by roller compaction (50KN) and granulation. The granules could be made up into a mixture  
5 suitable for a sachet presentation with the extra-granular excipients.

The granulate of this example could be supplied containing appropriate weights of amoxycillin/clavulanate in a sachet, and is also suitable for making up into syrup formulations. For example the weights listed may  
10 be made up into 60ml to produce a 156.25mg/5ml syrup or double the listed weights may be made up into 60ml to produce a 312.5mg/5ml syrup. These syrups do not contain any added sugar.

#### Example 9: Granulate

15

<u>Component</u>	<u>Weight mg.</u>	<u>Weight %</u>
Amoxycillin trihydrate	581.4 <sup>1</sup>	64.0
Potassium clavulanate	152.4 <sup>2</sup>	16.8
Syloid AL-1	152.4	16.8
Polyplasdone XL dried	22.0	2.42

as granulate

(1) corresponds to 500mg amoxycillin free acid.

(2) corresponds to 125mg free clavulanic acid.

20 Granules are prepared using this mixture in a manner identical to that of example 8. These granules are suitable for supply in a sachet, together with flavour and sucrose in the proportions listed below for the quantity of granules listed above per sachet:

Lemon dry flavour	136.0mg
Strawberry dry flavour	44.0mg
Peach dry flavour	34.0mg
Sucrose	to 3500mg

25

Sachets containing other weights of amoxycillin, e.g. 250 or 125mg could be made up using proportional amounts of the weights listed and made up to 1750mg total weight with sucrose.

5 Example 10: Tablet

<u>Component</u>	<u>Weight mg.</u>	<u>Weight %</u>
Amoxycillin trihydrate	581.4 <sup>1</sup>	61.2
Potassium clavulanate	152.4 <sup>2</sup>	16.0 as granulate
Syloid AL-1	152.4	16.0
Polyplasdone XL dried	17.4	1.83
Dry flavour (Peppermint or mandarin)	6.0	0.63
Polyplasdone XL dried	25.0	2.63 extra granulate
Aspartame	15.0	1.58
Colouring	5.0	0.53
Magnesium stearate	2.5	0.26

(1) corresponds to 500mg amoxycillin free acid.

(2) corresponds to 125mg free clavulanic acid.

10

Granules are prepared using this mixture in a manner identical to that of example 8. The flavour, polyplasdone XL, colouring and magnesium stearate were sieved then blended with the granulate. The aspartame was then added, and this mixture was then compressed into tablets on a

15

conventional tableting machine. This tablet contains 625.0mg of the amoxycillin: clavulanate combination, and the quantities used may be halved to prepare a tablet containing 312.5mg.



Example 11: Tablet

<u>Component</u>	<u>Weight mg.</u>	<u>Weight %</u>
Amoxycillin trihydrate	290.7 <sup>1</sup>	46.3
Potassium clavulanate	152.4 <sup>2</sup>	24.3
Syloid AL-1	152.4	24.3
Polyplasdone XL dried	8.7	1.38
Dry flavour (Peppermint or mandarin)	3.0	0.48
Polyplasdone XL dried	12.5	2.00
Aspartame	7.5	1.19
Colouring	2.5	0.39
Magnesium stearate	1.25	0.20

] as granulate

] extra granulate

- (1) corresponds to 250mg amoxycillin free acid.  
 5 (2) corresponds to 125mg free clavulanic acid.

Tablets were made from this mixture using a procedure identical to that of example 10.

10 Example 12 : Sachet or Syrup Formulations

<u>Component</u>	<u>Weight mg</u>	<u>w + %</u>
Amoxycillin : potassium clavulanate 4 : 1 w : w + 3 wt% CLPVP	2255.6	63.3
CLPVP	13.5	0.38
Lemon dry flavour	408.0	11.46
Strawberry dry flavour	132.0	3.71
Peach dry flavour	102.0	2.86
Silicon dioxide USNF (Syloid AL-1)	450.0	12.64
Aspartame	45.0	1.26
Xantham gum	150.0	4.21
Total weight	3561.6	100.0

] granulate<sup>1</sup>

- 16 -

(1) amox : clav expressed as free acid.

The granulate was prepared using the procedure of example 8. This formulation could be supplied in a sachet, or could be made up into a  
 5 syrup, for example at concentrations of 3561.6 mg/60ml or 7123.2 mg/60 ml or 7123.2 mg/60 ml (= 156.25 and 312.5 mg amoxycillin : clavulanate / 5 ml respectively). To adjust the syrup to a suitable viscosity and pH, aerosil 200, succinic acid and/or methocel E - 15 (dry) may be used.

10 Example 13 : Sachet Formulation

<u>Component</u>	<u>Weight (mg)</u>				<u>w +%</u>
Granulate (Amox:Kclav 4:1 or 7:1 + 3% PVP)	500	250	125	875	7-25
Lemon dry flavour	136	68	34	136)	
Strawberry dry flavour	44	22	11	44)	3-6.1
Peach dry flavour	34	17	8.5	34)	
Silicon Dioxide U.S.N.F. (Syloid AL-1)	150	75	37.5	150	2.1-4.3
Sucrose	to 3500	1750	1750	3500	to 100

(1) weights and Amox/Kclav expressed as free acid.

15 The granulate was prepared using the procedure of example 8, and was then mixed with the other excipients.

Example 14 : Tablet FormulationAmox : clav<sup>1</sup>

4 : 1

4 : 1

2 : 1

7 : 1

<u>Component</u>	<u>weight (mg)</u>				<u>w + %</u>
Granulate <sup>2</sup>	751.9	376.0	452.1	1201.3	70.90
Dry Flavour <sup>3</sup>	6.0	3.0	3.0	8.0	0.48 - 0.63
Poliplasdone XL) dried )	100.0	50.0	66.5	110.0	8.1 - 10.7
Aspartame	15.0	7.5	7.5	15.0	1.1 - 1.6
Colouring	4 - 5	2 - 2.5	2 - 2.5	4 - 5	0.3 - 0.55
Mag. Stearate	2.5	1.25	1.25	3.4	0.19 - 0.26
Silicon Dioxide )					
Syloid AL - 1 ) to	950	475	628	1350	to 100

- (1) Amox : clav expressed as weight : weight of amoxycillin :  
 5 clavulanate free acid.  
 (2) Granulate = amox : clav + 3% CLPVP.  
 (3) Peppermint or mandarin.

10 The granulate was prepared using the procedure of example 9.

The granulate was prepared using the procedure of example 9. The other excipients except aspartame were sieved and blended then mixed with the granulate. The aspartame was then added, and this mixture was then compressed into tablets in a conventional tableting machine. This tablet  
 15 contained 625 mg of the amoxycillin : clavulante blend. Tablets of different strengths could be formulated correspondingly, eg containing 1000, 375 or 312.5 mg of the amoxycillin : clavulanate combination.

Example 15 : Tablet Formulation

<u>Component</u>	<u>Weight (mg)</u>				<u>w +%</u>
Granulate (Amox.Kclav) 4:1 or 7:1 + 3% PVP	751.9	376.0	188.0	1201.3	71 - 83
Magnesium stearate	2.6	1.3	0.65	3.9	0.25 - 0.27
Ph. Eur					
Silicon Dioxide USP /NF (Syloid AL-1)	44.0	22.0	11.0	44.0	3 - 4.25
Microcrystalline cellulose	850.0	425.0	212.5	1275.0	1.8-5
Avicel pH 112 dried ...to..					
Organic film coating	yes	yes	yes	yes	to 100
Actual weight	1050.0	-	-	1450.0	

(1) amox : clav expressed as free acid.

5

The tablet was made up in a manner identical to that of example 14.

The weights and relative proportions of the components of examples 1 to 15 could be varied about the figures listed, but suitably are within  $\pm 10\%$  of those listed, desirably within  $\pm 5\%$ , especially  $\pm 2.5\%$ .

10

### Claims

1. A tablet formulation having a structure comprising compacted granulates; the granulates comprising at least one compacted medicament optionally together with an intra-granular disintegrant; the granulates being compacted together into a tablet form together with an extra-granular disintegrant and optionally also together with an extra-granular lubricant, provided that if a lubricant is present the amount of lubricant is less than 0.5% by weight of the total tablet.
2. A tablet formulation according to claim 1 wherein the medicament is a  $\beta$ -lactam antibiotic, optionally in combination with a  $\beta$ -lactamase inhibitor.
3. A tablet formulation according to claim 2 wherein the antibiotic is amoxycillin, optionally in combination with clavulanic acid or a salt thereof in a weight ratio equivalent to amoxycillin : clavulanic acid in the range 12 : 1 to 1 : 1.
4. A tablet formulation according to claim 1, 2 or 3 wherein the intra-granular disintegrant is selected from maize starch, rice starch, cross linked N-vinyl-2-pyrrolidone ("CLPVP"), sodium starch glycollate, croscarmellose sodium, formaldehyde-casein or combinations thereof.
5. A tablet formulation according to any one of the preceding claims wherein the proportion of intra-granular disintegrant is 0.1 to 10 wt % of the weight of the granulate.
6. A tablet formulation according to any one of claims 1 to 5 in which the granulate comprises a medicament which is amoxycillin or amoxycillin + clavulanic acid or a salt thereof in combination, an intra-granular disintegrant which is CLPVP or sodium starch glycollate, and optionally one or more diluent(s), in a proportion 70-99 wt % medicament, 1 - 5 wt % disintegrant and up to 30 wt % diluent.
7. A tablet formulation according to any one of the preceding claims wherein the granulate comprises 70 wt % or more of the tablet weight.

8. A tablet formulation according to any one of the preceding claims in which the extra-granular disintegrant is selected from maize starch, rice starch, CLPVP, sodium starch glycollate, croscarmellose sodium, microcrystalline or microfine cellulose, low-substituted
- 5 hydroxypropylcellulose, cross-linked sodium carboxymethylcellulose, swellable ion exchange resins, formaldehyde-casein, or alginates.
9. A tablet formulation according to any one of the preceding claims wherein the proportion of extra-granular disintegrant in the tablet is
- 10 between 0.1 - 25 wt % of the total tablet weight.
10. A tablet formulation according to any one of the preceding claims which contains 0 - 0.35 wt % lubricant.
- 15 11. A pharmaceutical granulate formulation comprising a medicament which is a  $\beta$ -lactam antibiotic together in combination with a  $\beta$ -lactamase inhibitor.
12. A formulation according to claim 11 wherein the medicament is
- 20 amoxycillin in combination with clavulanic acid or a salt thereof in a weight ratio equivalent to amoxycillin: clavulanic acid in the range 12:1 to 1:1.
13. A formulation according to claim 11 or 12 wherein the formulation
- 25 additionally includes an intra-granular disintegrant.
14. A formulation according to claim 13 wherein the disintegrant is selected from maize starch, CLPVP, sodium starch glycollate, croscarmellose sodium, formaldehyde-casein or combinations thereof.
- 30 15. A formulation according to claim 13 or 14 wherein the proportion of intra-granular disintegrant is 0.1 to 10 wt % of the formulation.
16. A formulation according to claim 11 in which the granulate
- 35 comprises a medicament which is amoxycillin plus clavulanic acid or a salt thereof in combination, an intra-granular disintegrant which is CLPVP or sodium starch glycollate, and optionally one or more diluent(s) in a proportion 70-99 wt % medicament, 1-5 wt % disintegrant and up to

30 wt % diluent.

17. A formulation according to any one of claims 11 to 16 or a granulate as defined in claim 1 or a granulate as defined in claim 1 when  
5 encapsulated in a pharmaceutical capsule.

18. A process for the manufacture of a pharmaceutical tablet, in which granulates comprising at least one compacted medicament optionally together with an intra-granular disintegrant are mixed with an extra-  
10 granular disintegrant and optionally with an extra granular lubricant and excipients, provided that if a lubricant is present it amounts to less than 0.5 wt % of the mixture, and the mixture is compressed into tablets.

19. A process for the manufacture of a pharmaceutical granulate, in  
15 which a medicament which is a  $\beta$ -lactam antibiotic together in combination with a  $\beta$ -lactamase inhibitor is compacted under pressure, optionally together with an intra-granular disintegrant.

20. A process according to claim 19 wherein the compaction is carried  
20 out using roller compaction.

21. A pharmaceutical formulation according to any one of claims 1 to 17 for use as an active therapeutic substance.

22. A pharmaceutical formulation according to any one of claims 1 to  
25 17, in which the medicament is a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, for use in the treatment of bacterial infections.

23. A method of use of a pharmaceutical formulation according to any  
30 one of claims 1 to 17 in which the medicament is a  $\beta$ -lactam antibiotic optionally in combination with a  $\beta$ -lactamase inhibitor, in the manufacture of a medicament for use in the treatment of bacterial  
infections.

35

**THIS PAGE BLANK (USPTO)**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**